Skip to content

Home
Wins
Flops
Big movers
Daily roundups

Duchenne Muscular Dystrophy trial results

Search drug, company, condition, ticker or NCT ID

Outcome

Phase

Condition

Company

Company type

Patients

Stock move (24h)

Announced

QuickWins Flops Big movers Today Phase 3 flops

PhasesPhase 1 Phase 1/2 Phase 2 12 Phase 2/3 1 Phase 3 13 Phase 4

Top conditionsSchizophrenia 2 Pulmonary Hypertension 2 Generalized Anxiety Disorder 2 Mycobacterium Infections, Nontuberculous 1 Autism Spectrum Disorder 1 Relapsed Diffuse Large B-Cell Lymphoma 1 Atopic Dermatitis 1 Idiopathic Hypersomnia 1 Hidradenitis Suppurativa 1 Duchenne Muscular Dystrophy 1

1 resultDuchenne Muscular Dystrophy ×

Met endpointMay 14, 2026

RGX-202

Phase 3 Duchenne Muscular Dystrophy

REGENXBIO RGNX

24h stock move▼ −38.15%

Drug trial results and the stock moves that follow

Outcomes

All wins
All flops
Met endpoint
Missed endpoint
Terminated / discontinued
Mixed results
Trial update

Phases

Phase 1
Phase 2
Phase 2/3
Phase 3
Phase 4

Explore

All results
Public companies
Big movers
Daily roundups

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.

© 2026 DrugTrials.org